1) Of these, 146 patients (one responder, 126 virologic responde

1). Of these, 146 patients (one responder, 126 virologic responders, and 19 nonresponders) had a treatment gap of ≤35 days between the last study dose in ETV-022 and the first study dose in ETV-901 and were considered continuously treated. These 146 patients constituted the nucleoside-naïve HBeAg-positive entecavir long-term cohort. Among the 146 patients in the entecavir long-term cohort, 68% (99/146) received entecavir through 5 years. Forty-seven patients

discontinued treatment Dasatinib datasheet prior to the Year 5 visit. The reasons for treatment discontinuation were: completion of treatment in the opinion of the investigator (12), progression of CHB (1); death (5); loss to follow-up (2); patient noncompliance (1); withdrawal of consent (14); minimal virologic response (3); and other (9). Mean time on therapy for the entecavir long-term cohort (n = 146) through studies ETV-022 and ETV-901 was 248 weeks. Of the 146 patients, 132 received entecavir in ETV-022 and entecavir together with lamivudine in study ETV-901, and 14 received only entecavir through both studies. Of the 132 patients who received entecavir with lamivudine in study ETV-901, 12 received the combined regimen only (mean exposure to lamivudine was 26.4 weeks) Selleck Doxorubicin and 120 received entecavir without lamivudine after initially receiving both (mean exposure to entecavir and lamivudine were 169 and 25.5 weeks, respectively). Baseline (pretreatment) demographic and disease selleck inhibitor characteristics

for the entecavir long-term cohort are presented in Table 1. The majority

of patients in the cohort were male (80%) and Asian (64%), with a mean age of 36 years. Mean baseline levels of HBV DNA and ALT were 9.9 log10 copies/mL and 122 IU/L, respectively. Infection with HBV genotype A (26%), B (27%), or C (30%) accounted for most patients; 4% were infected with HBV genotype D. HBV DNA was suppressed early in therapy and extended treatment increased or maintained viral suppression through Year 5 (Fig. 2). Mean change from baseline in HBV DNA at Year 5 was −7.2 log10 copies/mL. Fifty-five percent of patients in the cohort had achieved HBV DNA <300 copies/mL at Year 1 of the Phase III study (ETV-022; Fig. 3). The proportion of patients in the entecavir long-term cohort achieving HBV DNA <300 copies/mL increased from 55% in Year 1 to 83% in Year 2. Among 116 patients who had HBV DNA <300 copies/mL at Year 2, 109 (94%) achieved this response while receiving entecavir 0.5 mg daily in study ETV-022 and the other seven achieved the endpoint while receiving entecavir 1.0 mg ± lamivudine (in study ETV-901). Continuous treatment through Years 3, 4, and 5 resulted in increasing proportions of patients achieving and maintaining HBV DNA <300 copies/mL, with 94% (88/94) of patients achieving or maintaining this endpoint at Year 5. Figure 4 shows the distribution of patients according to HBV DNA level at Year 5; only one patient had HBV DNA >105 copies/mL.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>